

APTACHEM

Malmö 14 May 2020

PRESS RELEASE

Aptahem's latest patent application is registered in several countries

Aptahem today informs that the company's latest patent application has been registered in several countries and are subject to approval. The patent application, which is an international PCT application*, is a merger of two previous Europe applications and have now entered a so called country phase where the company has selected the most value increasing geographies. The patent application refers to Aptahem-1 and has the title "*A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties*".

The patent application was submitted in 2017 after achieving new, positive results in a number of preclinical studies. The scope of the protection is designed to cover the therapeutic protection for the company's lead candidate Aptahem-1 and the improvement of the molecular Aptahem-1 structure. The countries where the application now has been registered, or is in the process of registration, and awaiting approval are USA, Canada, Brazil, Japan, South Korea, China, Israel and Europe. The application in Europe will undergo an approval process and thereafter we will select the specific countries in Europe where we seek protection. The company will continuously inform the market about the country-specific approvals as they will be announced.

Aptahem's CEO, Mikael Lindstam, comments: "We are very pleased to see that this PCT application is one step closer to strengthen our protection of Aptahem-1 by entering the country phase in the countries we have selected as the most value increasing from a strategic perspective. The interest from the potential licensing and collaboration partners we are in discussions with will be intensified and significantly increased for both Aptahem as a company and for our product Aptahem-1."

The PCT application, with number WO/2019/068766, and the document can be read in full via updated, publicly available data basis.

** Patent Cooperation Treaty, PCT, is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications. The granting of patents remains under the control of the national or regional patent Offices in what is called the "national phase".*

Source: World Intellectual Property Organization (WIPO, www.wipo.int)

For further information:

Aptahem AB

Mikael Lindstam, CEO

Tel: +46 (0)766-33 36 99

Email: ml@aptahem.com

APTACHEM

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.